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Abstract
Background: Smoking and chronic kidney disease are major public health problems with common features -high
prevalence and mortality, high cardiovascular risk, gender differences and high prevalence in low income people-, but the
link between them is poorly recognized. Our objectives were to investigate the exposure of dialysis patients to tobacco
and to know their smoking behavior.
Methods: We performed a multicenter, cross-sectional study in nine dialysis units in the Argentinian Northern Patagonia.
We investigated smoker status, lifetime tobacco consumption, current tobacco use, breath carbon monoxide and %
carboxyhaemoglobin. Fagerström and Richmond tests were performed for active smokers. Statistical analysis: one way
ANOVA and Tukey’s test for post hoc test. For exploratory analysis, frequency tables through chi-square distribution and
single correspondence analysis were performed.
Results: Six hundred thirty six patients (60.9 % males, 39.1 % females) were interviewed. Almost 70 % of them had had
tobacco exposure. Excluding light smokers, the lifetime consumption was significantly different (p= 0.0052) between
sexes (33.1 ± 2.4 pack/years in males and 18.2 ± 2.1 pack/years in females) The distribution of etiologies changed
significantly (χ2p < 0.0001) with smoker status and the dose of tobacco smoking, with an increase in the diagnosis of
nephrosclerosis in patients with high and very high lifetime consumption (from 16.1 % in non-smokers to 28.2 and 27 %
respectively), and in passive smokers (from 16.1 to 27.3 %). The male preponderance of end-stage renal disease
disappeared when only non-smokers were considered and grew with the increase in the lifetime consumption. Active
smokers have small consumption, both low CO level and % COHb, low dependence and a good motivation to quit, but
a high lifetime consumption.
Conclusions: Exposure of dialysis patients to tobacco is high and could be related to the progression to the final stage of
the renal disease. It seems that tobacco renal damage is mostly hidden in the diagnosis of nephrosclerosis. The gender
difference observed in these patients could also have a nexus with the men’s higher tobacco exposure. Active smokers
have a low current consumption but a high lifetime tobacco dose.
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Resumen
Introducción: Tabaquismo y enfermedad renal crónica son importantes problemas de salud pública que
comparten: alta prevalencia, alta morbi-mortalidad, alto riesgo cardiovascular, diferencias de género y mayor
prevalencia en personas de bajos ingresos. Sin embargo, el nexo entre ellas es poco reconocido. Objetivos:
mensurar la carga tabáquica de los enfermos en diálisis y conocer su patrón de consumo.
Material y métodos: Participaron nueve unidades de diálisis de la Norpatagonia Argentina. Investigamos condición
de fumador, carga tabáquica y, en fumadores activos, consumo actual, tests de Richmond y Fagerström, monóxido
de carbono en aire espirado y % de carboxihemoglobina. Análisis estadístico: ANOVA de una vía y test de Tukey
para análisis post hoc. En el análisis exploratorio, utilizamos tablas de frecuencias a través de la distribución Ji
cuadrado y análisis de correspondencia simple.
Resultados: Seiscientos treinta y seis pacientes (60.9 % varones, 39.1 % mujeres) fueron encuestados. Casi un 70 %
de ellos había estado expuesto al tabaco. Excluyendo los fumadores leves, la carga tabáquica (CT) fue 33 ± 2.4
paquetes/año en hombres y 18.2 ± 2.1 paquetes/año en mujeres (p = 0.0052). La distribución de las etiologías de
ingreso a diálisis cambió significativamente (χ2p < 0.0001) según el estado de fumador y la CT, con aumento en el
diagnóstico de nefroesclerosis en fumadores pasivos (de 16.1 % en no fumadores a 27.3 %) y en pacientes con
elevadas CT (de 15.2 y 16 % en CT leve y media a 28.2 y 27 % en CT alta y muy alta). La preponderancia masculina
de la población desapareció en no fumadores y creció con el incremento en la CT (χ2p < 0.0001). Los fumadores
activos tienen bajo consumo, bajo nivel de CO y carboxihemoglobina, baja dependencia y están bien motivados
para dejar, pero tienen una elevada CT.
Conclusiones: La alta CT de los enfermos en diálisis podría generar o contribuir a la progresión de la enfermedad
renal crónica. El daño renal por tabaco se esconde principalmente en el diagnóstico de nefroesclerosis y se
relaciona con la CT. La diferencia de género de estos pacientes podría relacionarse con su exposición al tabaco. Los
fumadores activos tienen bajo consumo pero elevada CT.
Background
Chronic kidney disease (CKD) is now a worldwide public
health priority [1], not only for the increasing tendency but
also for the high risk for cardiovascular(CV) complications
related to renal function loss. CV disease is 10–20 times
higher in end-stage renal disease (ESRD) patients and their
most important cause of death [2]
Smoking is another major public health problem associ-
ated with CV and renal disease in the long term [3, 4].
However, around 15 % of incident dialysis patients smoke
and over 60 % report previous tobacco use [5]. Smoking
and CKD have common features: high prevalence [6, 7],
high mortality [8, 9] high cardiovascular risk [10, 11] gen-
der differences [12, 13] and both of them are linked to
poverty [14, 15].
However, the nexus between both diseases has been
underestimated, neglected or poorly recognized in
nephrologycal and tobacco fields. On the other hand,
the continued growth of the ESRD population around
the world has been related to the underrecognition of
earlier stages of CKD and risk factors for their devel-
opment [16] such as hypertension, diabetes, obesity
and smoking [17].
Clearly, the demographics of dialysis population has
changed dramatically since the start of chronic dialysis
in three essential aspects: etiology, incident age and
presence of comorbid conditions. In the seventies,
chronic glomerulonephritis and pielonephritis were the
two more frequent causes of entry to renal replacement
therapy as shown in registries [18] of that time. In fact,
both represented 75 % of the total dialysis population
and, surprisingly, the “microscopic renal vascular dis-
ease” (nephrosclerosis) represented only 3.5 % of etiolo-
gies and “diabetic glomerulonephritis” appeared in the
list of “rarer diseases”. Back then, the majority of pa-
tients were 20–54 years old when treatment com-
menced. On the contrary, in the last years, the leading
causes of ESRD are diabetes and nephrosclerosis, [19]
the mean age increased about a decade [20] and comor-
bid conditions rose dramatically [21]. In Argentina, it is
more and more frequent to see incident dialysis patients
with several previous vascular interventions (by-pass sur-
gery, stenting, angioplasty) or comorbid conditions dir-
ectly related to the smoking status (kidney, urinary tract
or lung carcinomas). Also, it is usual to see patients smok-
ing outside of the dialysis units while they are waiting for
the dialysis session to begin or the arrival of the transfer
vehicle to return home.
When in 2011 we analyzed our first results about the
prevalence of smoking in dialysis units of Northern Patago-
nia Association of Nephrology (Abstract XVII Argentinian
Congress of Nephrology), we were surprised by the high
number of patients (75 %) with some history of tobacco
exposure.
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The purpose of this research work was to measure the
exposure to tobacco of ESRD patients in Argentinian
Northern Patagonia in March-April 2013 and to get to
know their pattern of tobacco use.
Methods
A multicenter, cross-sectional study was conducted in
March-April 2013 to assess the smoking history and habits
of ESRD patients in Argentinian Northern Patagonia. The
thirteen dialysis units in the “Comahue region” were
invited to participate in the study but only nine responded.
The survey consisted of a questionnaire in order to know
smoking status, lifetime consumption, current tobacco use,
motivation to stop, nicotine physical dependence and
history of other addictions. The two principal investigators
visited each dialysis unit and interviewed patients face to
face during the hemodialysis session or during the monthly
control in the case of peritoneal dialysis patients. Medical
records were reviewed to obtain information about time
on dialysis and the diagnosis of renal disease. All patients
interviewed were briefly informed about the risks of
smoking (focus on CV, vascular access and transplant
risk) at the end of each interview and were offered
counseling to stop in the case of active smokers. Also,
the workers of the centers were informed about risks
and trained in how to stimulate patients to stop.
Smoking status
Participants were divided into four groups: nonsmokers
(those who had never smoked or had smoked under 100
cigarettes in their life), past smokers (those who had
smoked more than 100 cigarettes in their life and had
stopped smoking at least one year before the study entry),
current smokers (who smoked at the moment of interview
and had smoked at least 100 cigarettes in their life) and
passive smokers (people exposed to environmental tobacco
for at least 10 years).
Lifetime tobacco consumption (LTC)
It was estimated in pack-years. Pack-years were calculated
by dividing the mean number of cigarettes smoked a day by
20 and multiplying with the number of smoking years. The
LTC was calculated in current and past smokers and con-
sidered light if < 5 pack/year, moderate if 5–15 pack years,
heavy if 16–25 pack-years and very heavy if > 25 pack-years.
Current smokers
The smokers’ clinical history was performed for each active
smoker including the Fargeström and Richmond tests as
well as the determination of breath carbon monoxide in
parts per million (ppm CO) with the piCO+ Smokelyzer.
Blood carboxyhaemoglobin in percentages (% COHb) was
calculated with the formula CO ppm x 0.16.
Statistical analysis
Data was analyzed with InfoStat/P v.2013 [22] Results
are shown as mean ± SEM for continuous variables, and
number and percentages for categorical variables. Com-
parison between variables was carried out through one
way ANOVA and the post hoc test used was Tukey’s
testing. In order to determine the relation between vari-
ables, frequency tables through chi-square distribution
were carried out. Besides when a relation did exist, sin-
gle correspondence analysis was performed. Significant
level was considered p-values <0.05.
Results
Baseline characteristics
Six hundred thirty six patients (60.9 % males, 39.1 %
females) from nine dialysis units in Argentinian Northern
Patagonia (Comahue region) were interviewed. This region
includes two provinces, Río Negro and Neuquén, with
1,189,911 inhabitants, according to the last population cen-
sus in 2010 (INDEC) [23] In both provinces, in December
2012, there were 1,185 patients under renal replacement
therapy according to the Argentinian Register of Chronic
Dialysis [19]; therefore, our sample included more than half
of this dialysis population.
These patients comprised 98 % of the total available
population (hospitalized patients or those who did not
attend the dialysis session the day of the survey, did not
take part in the study and only one patient refused to re-
spond) Their mean age was 57.3 ± 0.6 years. The mean time
on renal replacement treatment was 68.4 ± 2.5 months and
the treatment modality was hemodialysis in 596 patients
and peritoneal dialysis in 40 patients. The etiologies of end-
stage renal disease were: glomerulonephritis (GN) 18 %,
nephrosclerosis (NS) 19.2 %, obstructive uropathy (OU)
6.1 %, diabetes (DBT) 22.5 %, unknown (UK) 22.6 % and
others (OT) 11.5 %.
Smoking status (SS)
There were 93 (14.6 %) current smokers and 543 (85.4 %)
non- current smokers. In the last group, 269 (49.5 %) were
never smokers, and 274 (50.5 %) were former smokers. But
in the group of never smokers there were 77 (28.6 %)
passive smokers (past or present). Therefore, almost 70 %
of the population had had tobacco exposure.
Lifetime tobacco consumption (LTC)
It was calculated in current and past smokers and was very
high (>25 pack/years) in 24.4 %, high (16–25 pack/years) in
10.2 %, moderate (5–15 pack/years) in 21.6 % and light (<5
pack/years) in 43.7 %. Excluding light smokers, the mean
LTC was 33.1 ± 2.4 pack/years in males and 18.2 ± 2.1
pack/years in females (p = 0.0052). The distribution of
etiologies varied significantly (χ2p < 0.0001) according to
smoker status (Table 1) and LTC (Table 2).
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The diagnosis of nephrosclerosis increased in all categor-
ies of smoker but passive smokers showed a more import-
ant increase (from 16.1 % in non-smokers to 27.3 %). In
smokers with high and very high LTC, the percentages
grew from 15.2 and 16 % in light and medium LTC to 28.2
and 27 % respectively.
Gender
Sex distribution differs significantly (χ2p < 0.0001)
according to SS (Table 3).
In never smokers it was 54.2 % for women and 45.8 % for
men, whereas in current and former smokers we observed
male preponderance (75 %). If we consider only current
and former smokers with high and very high LTC, the per-
centage rose to 85 %. Instead, female preponderance was
observed in passive smokers. We also made a simple cor-
respondence analysis to observed associations between age,
gender and smoker status. Active smokers were younger
than former smokers. Male gender was associated to past
smoker and age over 40 years whereas female gender was
related to non-smoker and passive smoker.
Current smokers
17.8 % of males and 9.6 % of females were smokers
(n = 93). Their average age was 48.3 ± 1.6 years, of which
74.2 % were males and 25.8 % were females. Current to-
bacco use was <10 cigarettes/day in 68.8 % of cases, be-
tween 11–20 cig/d in 15 %, more than 20 cig/d in 5.3 %
and there were another 10.8 % of patients with recent
quitting (less than one year) that we cannot yet consider
former smokers. Only one patient consumed more than
31 cig/d. LTC was very high in 35 smokers, high in eight,
moderate in 25 and light in the other 25. According to
Richmond test, 26.9 % of patients were in the pre-
contemplation stage, 39.8 % in the contemplation stage
and 22.5 % in preparation phase (high motivation for quit-
ting). According to Fagerström test, dependence was low
in 90.3 %. Other addictions were informed in 24 cases (al-
cohol, analgesic or illegal drugs). Average level of breath
CO was 10.8 ± 0.8 ppm and % COHb 1.7 ± 0.1.
Discussion
According to our investigation, it seems that dialysis
units are nowadays bastions of heavy smokers (past or






Current (% and 95 % CI) Never (% and 95 % CI Passive (% and 95 % CI Former (% and 95 % CI
Diabetes 14 (6–21.9) 24.5 (20.6-28.3) 22 (21.7-22.4) 24 (19.7-28.5) 143 (22.5)
Glomerulonenephritis 28 (18.8-37.1) 18.2 (17.9-18.5) 13 (9–16.9) 16 (10.5-21.6) 115 (18.1)
Nephrosclerosis 19.3 (19.2-19.5) 16.1 (10.3-21.9) 27.3 (21–33.5) 19 (18.4-19.5) 122 (19.2)
Unknown 23.7 (22.7-24.6) 25.5 (19.9-31) 16.9 (12.4-21.3) 22 (19.8-23.9) 144 (22.6)
Obstructive uropathy 0 5.7 (4.9-6.5) 5.2 (4.4-5.9) 8.8 (1.5-15.9) 39 (6.1)
Others 15 (11.7-18.3) 10 (6.8-12.9) 15.6 (12.4-18.7) 10.2 (6.7-13.6) 73 (11.5)
Total (number and %) 93 (14.6) 192 (30.2) 77 (12.1) 274 (43.1) 636 (100)
The change in etiology distribution achieved statistical significance (χ2 = 82.34; p < 0.0001), with an important increase (from 16.1 % to 27.3 %) in nephrosclerosis
in passive smokers (bold text)
Table 2 Etiologies and lifetime tobacco consumption in past and current smokers
Etiology of end-stage
renal disease
Lifetime tobacco consumption (% and 95 % CI) Total
(number
and %)
Light <5 pack/years Medium 5–15 pack/years High 16–25 pack/years Very high >25 pack/years
Diabetes 19.6 (16.6-22.6) 24.7 (22.1-27.2) 15.4 (13–17.8) 24.7 (21.9-27.6) 79 (21.5)
Glomerulonephritis 23.4 (16.5-30.2) 19.8 (19.2-20.3) 12.8 (10.4-15.3) 13.5 (8.5-18.5) 70 (19.1)
Nephrosclerosis 15.2 (8.2-22.2 16 (13.2-18.9) 28.2 (24.9-31.6) 27 (20.4-33.5) 72 (19.6)
Unknown 23.4 (20.8-26) 19.8 (18.1-21.4) 28.2 (25.7-30.7) 18 (14.6-21.4) 80 (21.8)
Obstructiveuropathy 6.3 (5.6-7) 3.7 (1.2-6.2) 2.6 (0.9-4.2) 12.4 (7.4-17.3) 25 (6.8)
Others 12 (10.7-13.4) 16 (12.1-20) 12.8 (12.2-13.5) 4.5 (1.45-10.4) 41 (11.2)
Total (number and %) 158 (43) 81 (22) 39 (11) 89 (24) 367 (100)
Lifetime tobacco consumption (LTC) was calculated in pack-years. The change observed in etiology distribution achieved statistical significance (χ2 = 42.23; p <
0.0001). The diagnosis of nephrosclerosis increased from 15.2 % and 16 % in patients with light and medium LTC to 28.2 % and 27 % in patients with high and
very high LTC (bold text)
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current) surviving thanks to modern medical advances.
They have a low current consumption but an important
lifetime consumption which might have influenced the
progression to ESRD and could contribute to the gender
difference observed in this disease. Also the exposure to
second hand smoke could have a nexus with chronic
kidney disease.
The suspicion that smoking could be a kidney risk factor
dates back to the first half of the 20th century [24] but it
took many years for the evidence supporting this suspicion
to make itself present. Smoking was pointed out for the
first time as a renal risk factor 35 years ago (1978) when
Christiansen [25] reported a more rapid progress of dia-
betes nephropathy in smokers, and Dales [26] observed that
the presence of proteinuria was more common in smokers
and more prominent in heavy smokers. In the final years of
the 20th century, prestigious nephrologists [27] highlighted
something that cardiologists, neurologists and vascular sur-
geons had concluded many years earlier: that smoking was
a vascular risk factor and, as a consequence, an important
renal risk factor such as diabetes or hypertension which, ba-
sically, induce renal damage by means of vascular damage.
However, for reasons difficult to understand, nephrologists
couldn’t accept something that seemed obvious if we con-
sider that the vascular renal network is one of the widest of
the body [28]. Perhaps, the reason for this omission is
related to the silent characteristics of renal disease: there
isn’t “renal angina”, the “vascular renal accident” is diag-
nosed only exceptionally, and the loss of renal function
does not generate dramatic situations such as a myocardial
infarction, a cerebral vascular accident, a member amputa-
tion or sexual disfunction. On the other hand, the delayed
nephrology consultation leads to a significant number of
patients starting renal replacement therapy without accur-
ate diagnosis.
The tobacco exposure of our patients was similar to that
reported by Banas et al. [29] in patients on the waiting list
for renal transplant (70 % of patients with tobacco expos-
ure). This observation confirms our suspicion that there is
more tobacco exposure in dialysis patients than in the
general population, where the exposure reaches 50 % [30]
In that survey, the percentage of current smokers was
higher (24 %) than in our investigation (14.6 %). Perhaps,
this difference is a result of the fact that patients on the
waiting list are younger, with less comorbidities, and
are healthy enough to be able to smoke. Our prevalence
of passive smokers was higher (28.6 %) than what was
reported on the general population (12 %) [31] but very
similar to what was reported in patients with coronary
heart disease [32]. Unfortunately, in the Banas study,
there was not information about these smokers.
The mean LTC found in our patients was higher than
that reported by Banas (33.1 pack-years for men and 18.2
pack-years for women vs 17 and 14.5 pack-years respect-
ively), but our analysis excluded smokers with <5 pack-
years and this could be the reason for the difference.
Moreover, our study included all dialysis patients and the
Banas study included only waiting list patients.
The etiologies of ESRD were comparable with those
reported by the ARCD. Three etiologies, diabetes (23 %),
nephrosclerosis (19 %) and unknown (23 %) lead the regis-
ter including 65 % of prevalent dialysis patients. However,
when we focus on passive smokers and smokers with
high and very high LTC, there is an important increase
in the diagnosis of NS, suggesting that in this diagno-
sis the heaviest tobacco burden is hidden. In a survey
on Swedish population, Ejerblad et al. [33] informed
about the increase in the diagnosis of NS with the
increase in LTC. We want to highlight the change ob-
served in passive smokers because this feature is very
important if we consider the reported relationship be-
tween passive smokers and vascular damage [34, 35].
Vascular, interstitial and glomerular lesions has been de-
scribed in long-term smokers but vascular damage is pre-
ponderant [36, 37]. Cigarette smoke damages endothelial
cells and nicotine induces smooth muscle cell proliferation
[38]. Our study is the first to inform about the exposure to
second hand smoke in ESRD patients.
The incidence and prevalence of ESRD is greater in men
than in women [39] but the underlying mechanisms are
not clearly identified. The factors involved may include
diet, glomerular and kidney size, differences in glomerular
hemodynamics or sex hormonal effects [40]. When we
analyzed only never-smoking patients, the male prepon-
derance disappeared, but it grew when we focused on
smokers (past and current), and grew even more with the
increase in tobacco exposure. When we looked at the
2012 ARCD [19], we were surprised by the fact that there




Current non smokers (% and 95 % CI)
Never Passives Former
Men (number = 387) 74.2 (61.2-86.6) 45.8 (45.8-74.6) 29.9 (6–53.7) 75.5 (35.3-115.8)
Women (number = 249) 25.8 (13.4-38.2) 54.2 (54.2-83) 70.1 (46.3-94) 24.5 (15.8-64.7)
All (number = 636) 93 192 77 274
Sex distribution differed significantly (χ281.84; p < 0.0001) according to smoking status. The male preponderance of ESRD disappeared when we considered only
never smokers and grew if we focused on former and current smokers; in passive smokers there was prominent female majority (bold text)
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are no gender differences until the age of 45, but in the
subsequent decades, the gender difference becomes
increasingly prominent. This leads us to think that the dif-
ference may be caused by a factor that takes a long time
to cause damage (tobacco?). Up to now there is not any
survey that has investigated the role of tobacco in the
greater prevalence of CKD on men, thus opening an inter-
esting research field.
Finally, current smokers were about a decade younger
than the total population with a relevant male preponder-
ance (74.2 % men). In most of them, the actual consump-
tion was low but LTC (>5 pack-years in 70 %) was high.
However, it has been reported that many persons quit
smoking only after the onset of severe illness [41] Indeed,
10.8 % of our patients had quit recently as a consequence
of the impact of starting dialysis, as was pointed out by
Banas et al. These patients gave us an excellent opportunity
to encourage quitting, focusing on the specific benefits to
quit [42] -lower obstruction rate of vascular access [43],
lower cardiovascular risk [44] and better post- transplant
evolution [45].
The Richmond test [46] was designed to know the
readiness of the smoker to stop smoking. Prochaska and
Di Clemente [47] developed the “stage of change model”
for assessing it. About 40 % of smokers in the general
population are not ready to quit and another 40 % are
“unsure”. Only 20 % of smokers are ready to stop. In the
case of our patients, if we add 22.5 % of patients ready to
stop to 10.8 % of patients with recent quitting, we have
33.3 % of patients with a good motivation to stop, which
outnumbers the reported percentages of these change
steps in the general population [48].
The Fagerström test [49] evaluates tobacco physical de-
pendence. When physical dependence is high, consump-
tion is also high and heavy smokers start to smoke early in
the morning in order to increase their falling nicotine
levels after night deprivation. Instead, smokers with ESRD
have a small consumption that usually starts after midday
and is influenced by the dialysis treatment: smokers with
ESRD smoke before the dialysis treatment to relax and
start smoking again very soon after the dialysis treatment.
If we consider that these patients have smoked for many
years and most of them have just had complications
related to tobacco, it seems difficult to believe that they
have “low dependence”. We think that our patients may
have tobacco psychological dependence that unfortunately
we have not investigated, and maybe, the Fagerström test
might require some changes for these particular patients.
Breath carbon monoxide is a risk marker for the devel-
opment of diseases related to tobacco and a valid indirect
marker of carboxyhaemoglobin level, with a linear rela-
tionship between them [50]. The mean level of carbon
monoxide of our patients (10.8 ppm) was a little over the
cutoff point of 8 ppm between smokers and non-smokers
[51] according to the low consumption reported by the
majority of them. We observed a similar feature in the
percentage of carboxyhaemoglobin (1.7 %) which has a
cutoff point of 1.66 % according to Jarzon et al. [52] How-
ever, these levels could be dangerous in the context of
ESRD patients, frequently anaemic, with an extremely
high cardiovascular risk.
Some smokers, such as smokers with COPD [53]
have specials patterns of tobacco consumption (higher
consumption, higher dependence and higher CO in
exhaled air). Instead, our dialysis patients have a small
current consumption, a low level of CO, low depend-
ence but an important LTC. Up to now, there has been
no information about the smoking habits of ESRD pa-
tients and our study is the first to explore them.
The personal contact between patients and the two
main investigators (especially trained in tobacco control)
is the greatest strength of our study. On the contrary, the
main limitations lie in the absence of a non-renal control
population, the limited sample size and the presence in
CKD patients of many confounding factors. Unfortu-
nately, we were not able to demonstrate associations
between LTC and non- renal complications linked to to-
bacco use because not all patients had been screened in
the same way (it was a multicenter, cross-sectional study).
However, if we add the present results to the cumulative
evidence since the start of this century, it seems absolutely
necessary to enlarge this cohort in order to achieve major
statistical power.
Conclusions
The high exposure of dialysis patients to tobacco (past,
passive or current) could be related to the increasing
worldwide tendency of end stage renal disease and to the
gender difference observed in this disease. The diagnosis
of nephrosclerosis seems to hide the most important
tobacco burden. Active smokers have low dependence,
good motivation to quit, low actual consumption but high
lifetime tobacco consumption. Nephrologists and tobacco
specialists should work together to find a marker of “to-
bacco nephropathy” that permits their inclusion as an
etiologic cause of ESRD.
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